– UK, Oxford – Summit Therapeutics plc (AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy (‘DMD’) and C. difficile infection (‘CDI’), announces the appointment of Mr David Wurzer as a Non-Executive Director.
“David Wurzer has extensive skills and expertise from his career in the pharmaceutical and biotechnology industry, and, on behalf of Summit, I am delighted to welcome him to the Board of Directors,” commented Dr Frank Armstrong, Chairman of Summit. “This is an exciting time for the company as we continue to explore a possible listing on NASDAQ to complement our existing AIM listing, as well as advance our DMD and CDI programmes through patient clinical trials. David’s expertise in financial matters and experience in working for US listed companies will be extremely valuable in supporting the future growth of the Company.”
Mr David Wurzer added, “I am very pleased to be joining Summit at this exciting and important period in its development. I very much look forward to working with the experienced board and management team at Summit as we seek to establish the benefit of our innovative DMD and CDI programmes as potential life-changing treatments.”
About Mr David Wurzer
Mr David Wurzer has extensive experience in business and financial matters relating to the pharmaceutical and biotechnology sector having held a number of senior executive and board level positions. Mr Wurzer was Executive Vice President, Treasurer and Chief Financial Officer of the NASDAQ listed biotechnology company CuraGen Corporation from 1997 to 2008. He also held a number of positions at Value Health Inc., from 1991 to 1997 including Senior Vice President, Treasurer and Chief Financial Officer. He is currently the Executive Vice President and Chief Investment Officer at Connecticut Innovations, a state funded venture capital fund. Mr. Wurzer is currently a Non-Executive Director on the boards of Response Genetics and Special Diversified Opportunities, Inc., and from 2010 to 2012 he was a Non-Executive Director on the board of DUSA Pharmaceuticals. Mr. Wurzer is a Certified Public Accountant and began his career with Coopers & Lybrand, which is now part of PricewaterhouseCoopers. He received a BBA from the University of Notre Dame.
About Summit Therapeutics
Summit is a drug discovery and development company targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection. Summit is quoted on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
